Matthieu Daugan, Director of the Cell-Mediated Immunity Platform at IQVIA Laboratories, delves into his background in immunology and virology, the intricacies of his current role, and the challenges and advancements in the field of vaccine development. Matthieu shares insights into the complexity of cell-mediated immunity, the importance of detailed scientific analysis, and the evolution of vaccine evaluation, particularly in light of recent global health challenges such as COVID-19. This discussion provides a comprehensive overview of the processes involved in analyzing immune responses and the significance of his team’s work at different stages of vaccine development.
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
